(MedPage Today) — The FDA has approved the topical phosphodiesterase 4 (PDE4) inhibitor difamilast (Adquey) as a new option for mild/moderate atopic dermatitis (AD).
The approval allows for use in adults and pediatric patients at least 2 years…
Source link : https://www.medpagetoday.com/dermatology/atopy/119913
Author :
Publish date : 2026-02-17 18:29:00
Copyright for syndicated content belongs to the linked Source.
